12 Best Healthcare Stocks to Buy for 2026

Page 10 of 11

2. AbbVie Inc. (NYSE:ABBV)

1-Year Gain: 25.49%

Upside Potential: 16.37%

Number of Hedge Fund Holders: 93

AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, $10.4 billion from Rinvoq, and EPS of $14.22, in line with consensus, while noting investor concerns about competition and smaller earnings beats.

Goldman anticipates a slight revenue beat in Q4, with Skyrizi performing above expectations and Rinvoq slightly below, alongside continued pressure on the Aesthetics business and steady results in Neurology and Oncology. AbbVie’s high P/E ratio of 168.95 reflects strong growth expectations, supported by its 3.09% dividend yield.

Earlier on January 16, AbbVie Inc. delivered mixed results in the phase 3 Lymphoma trial. The EPCORE DLBCL-1 trial for epcoritamab showed improved progression-free survival in patients.

The trial showed higher complete response rates and longer response durations. However, the candidate drug did not demonstrate a significant improvement in overall survival and did not meet the overall survival endpoint. Nevertheless, the adverse events were consistent with the candidate drug’s known safety profile.

In a bid to address the issues raised in the trials, AbbVie and its partner Genmab are assessing potential factors that may have negatively influenced the results. Some of the factors include the COVID-19 pandemic and the increased availability of novel anti-lymphoma therapies.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines and solutions for complex health issues, specializing in immunology, oncology, neuroscience, and eye care, and aiming to improve patient lives and societal health through targeted research, development, and strategic partnerships.

Page 10 of 11